Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. - Linkeschova,R.; Raoul,M.; Bott,U. (Diabetic Medicine, 2002)